Navigation Links
Talecris Biotherapeutics Announces First Quarter 2011 Results
Date:4/27/2011

7)(4,590)Other(60)(2)Changes in assets and liabilities:Accounts receivable(17,022)(31,252)Inventories(8,821)(3,136)Prepaid expenses and other assets11,3407,814Accounts payable(11,543)(12,386)Accrued expenses and other liabilities(21,552)(3,734)Interest payable11,62411,625Net cash provided by operating activities39,63430,670Cash flows from investing activities:Purchase of property, plant, and equipment(53,266)(17,690)Other190174Net cash used in investing activities(53,076)(17,516)Cash flows from financing activities:Borrowings under revolving credit facility302212Repayments of borrowings under revolving credit facility(302)(212)Financing transaction costs-(78)Repayments of capital lease obligations(205)(176)Proceeds from exercises of stock options1,3142,937Repurchases of common stock (2,199)(4,917)Excess tax benefits from share-based payment arrangements1,0774,590Net cash (used in) provided by financing activities(13)2,356Effect of exchange rate changes on cash and cash equivalents917(484)Net (decrease) increase in cash and cash equivalents(12,538)15,026Cash and cash equivalents at beginning of period197,87665,239Cash and cash equivalents at end of period$
85,338$
80,265EXHIBIT A:  MATTERS AFFECTING COMPARABILITYTalecris believes that the comparability of the financial results between the periods presented is significantly impacted by the following items:

Definitive Merger Agreement with Grifols The company incurred legal, accounting, and other fees of approximately $1.1 million associated with the definitive merger agreement with Grifols for which no amounts were incurred during the comparable prior year period.  The company is obligated to pay additional fees totaling $21.3 million to investment bankers upon successful closing of the merger transaction.  

Under the terms of the definitive merger agreement with Grifols, Talecris is permitted to offer retention amounts up to $15.0 million to employees.  As of March 31
'/>"/>

SOURCE Talecris Biotherapeutics Holdings Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
4. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
7. Talecris Added to NASDAQ Biotechnology Index
8. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
9. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
10. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
11. Talecris Biotherapeutics Announces Premerger HSR Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market ... $140 billion in 2013. This is estimated to grow ... annual growth rate (CAGR) of 28.6%. , New digital ... exciting possibilities within the broader PCR field. The opportunities ...
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... among stations to run 30-second spot on Pyratine XR(TM) and ... Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company ... of healthy aging, announced today that on June 27, 2009 ... XR(TM) (0.125% furfuryl tetrahydropyranyl adenine) and rosacea, a condition afflicting ...
... N.C., June 26 Syngenta Biotechnology, Inc. announced today ... and commercial license agreement for Chromatin,s proprietary gene stacking ... Chromatin has developed a novel approach to gene stacking, ... Under this agreement, Syngenta has obtained exclusive rights to ...
... EasyMax™ is a ... heating and cooling without an additional cryostat. For a limited time, METTLER TOLEDO is ... EasyMax™, and the chance to WIN A SKI WEEKEND* in St. Moritz, Switzerland or Colorado, ... Columbia, MD (PRWEB) ...
Cached Biology Technology:Television News Segment Featuring Pyratine XR to Air to 18 Million + Households on DIRECTV NewsCluster 2Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane 2Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane 3Register to Win a Ski Weekend and Make Your Synthesis Easier with EasyMax™: the First Automated Chemistry Development Tool That Requires No Training 2
(Date:7/11/2014)... available in German . ... that uses the refraction of X-rays through a specimen ... with this method are often of much higher quality ... team of Prof. Franz Pfeiffer are particularly interested in ... including X-ray phase-contrast imaging. One main goal is ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... accumulation of genetic damage in our cells is a major ... published today in the journal Nature by an international group ... critical gene for repairing damaged DNA grow old rapidly and ... that grow old naturally. Furthermore, the premature aging symptoms of ...
... transplant (HSCT) recipients face a significant long-term risk for ... at the time of transplant or received stem cells ... Published in the January 1, 2007 issue of CANCER ... Cancer Society, the study reveals that within 10 years ...
... researchers have developed a biochip that measures the electrical activities ... data in just one reading than is possible with current ... speed scientific research, which could accelerate drug development for muscle ... crop varieties. , "Instead of doing one experiment ...
Cached Biology News:Buildup of damaged DNA in cells drives aging 2Buildup of damaged DNA in cells drives aging 3Buildup of damaged DNA in cells drives aging 4Long-term cancer risk follows stem cell transplant recipients 2New biochip helps study living cells, may speed drug development 2New biochip helps study living cells, may speed drug development 3
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
...
Biology Products: